Patterns of response to aripiprazole, lithium, haloperidol, and placebo across factor scores of mania

Michael J Ostacher¹,²*, Trisha Suppes¹,², Alan C Swann³, James M Eудicone⁴, Wally Landsberg⁵, Ross A Baker⁶ and Berit X Carlson⁷

Abstract

Background: A previous factor analysis of Young Mania Rating Scale and Montgomery-Åsberg Depression Rating Scale items identified composite factors of depression, mania, sleep disturbance, judgment/impulsivity, and irritability/hostility as major components of psychiatric symptoms in acute mania or mixed episodes in a series of trials of antipsychotics. However, it is unknown whether these factors predict treatment outcome.

Methods: Data from six double-blind, randomized, controlled clinical trials with aripiprazole in acute manic or mixed episodes in adults with bipolar I disorder were pooled for this analysis and the previously identified factors were examined for their value in predicting treatment outcome. Treatment efficacy was assessed for aripiprazole (n = 1,001), haloperidol (n = 324), lithium (n = 155), and placebo (n = 694) at baseline, days 4, 7, and 10, and then weekly to study end. Mean change in factor scores from baseline to week 3 was assessed by receiver operating characteristics curves for percentage factor change at day 4 and week 1.

Results: Subjects receiving aripiprazole, haloperidol, and lithium significantly improved mania factor scores versus placebo. Factors most predictive of endpoint efficacy for aripiprazole were judgment/impulsivity at day 4 and mania at week 1. Optimal factor score improvement for outcome prediction was approximately 40% to 50%. Early efficacy predicted treatment outcome across all factors; however, response at week 1 was a better predictor than response at day 4.

Conclusions: This analysis confirms clinical benefits in early treatment/assessment for subjects with bipolar mania and suggests that certain symptom factors in mixed or manic episodes may be most predictive of treatment response.

Keywords: Aripiprazole; Bipolar disorder; Treatment outcome; Antipsychotic; Factor analysis; Mania

Background

Bipolar disorder has historically been described as discrete episodes of depression and mania. However, the structure of an episode is far more complex, and it has long been recognized that depressive and manic symptoms often exist simultaneously during periods of illness and can combine to create so-called ‘mixed states’ (Kraepelin 1921). Subsequent enquiries focused on mixed mania consisting of depressive symptoms during manic episodes (Kotin and Goodwin 1972; McElroy et al. 1992) or defined mixed states as a form of mania combining syndromal depression and mania (Swann et al. 2009). To date, there has been little consensus over the structure and definition of a mixed state, making a correct clinical diagnosis increasingly difficult. There is increasing evidence that depressive features may be a component across episodes of bipolar disorder (APA 2013; Swann et al. 2013a), leading to a new use of the concept of a ‘mixed-features specifier’ in the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-V) (APA 2013) rather than the previous term of mixed episodes as described in the DSM-IV, text revision (APA 2000). It
remains to be established, however, whether depression is a characteristic of manic episodes (mania is a characteristic of depressive episodes) or whether ‘mixety’ is a combination of independent depressive and manic states. Better understanding of the clinical structure of manic episodes in subjects with bipolar disorder may be useful in understanding treatment response and determining differences in efficacy based on symptom dimensions.

Several factor analyses exploring the symptomatic structure of manic episodes have confirmed the heterogeneity of manic and mixed episodes (Azorin et al. 2008; Bertschy et al. 2007; Cassidy et al. 1998; Dilsaver et al. 1999; Harvey et al. 2008; Lipkovich et al. 2008; Rossi et al. 2001; Sato et al. 2002; Swann et al. 2001), which has an impact not only on classification of bipolar disorder but also on the choice of treatment. Recent treatment algorithms sought to distinguish between euphoric (classical) mania, dysphoric mania and mixed states, psychotic mania, and hypomania to better personalize treatment (Grunze et al. 2009). Therefore, the symptomatic structure of bipolar disorder is of interest as it can potentially be used to differentially predict response to treatment and guide treatment choice.

One important aspect of treatment strategies for mania is the need for early clinical prediction of response to a particular treatment. Previous analyses showed that early response to lithium or ziprasidone predicted treatment outcome in acute manic and mixed episodes (Ketter et al. 2010; Swann et al. 1986). However, this topic has never been investigated using specific, clinically observable symptoms of manic or mixed episodes. Therefore, using the factor structure developed previously (Swann et al. 2013b), the relationship between early response and treatment outcome was investigated. The analysis was based on a series of randomized clinical trials that led to the approval of aripiprazole for acute manic and mixed states by the Food and Drug Administration (FDA): three double-blind, placebo-controlled, 3-week studies (El Mallakh et al. 2010; Keck et al. 2003; Sachs et al. 2006b), a double-blind, haloperidol-controlled, 12-week study (Vieta et al. 2005), and two active- and placebo-controlled, double-blind, 12-week studies (Keck et al. 2009; Young et al. 2009). Previously, baseline data from these combined studies was used to conduct a rotated factor analysis followed by a cluster analysis using all items from the Young Mania Rating Scale (YMRS) and the Montgomery-Åsberg Depression Rating Scale (MADRS) (Swann et al. 2013b) and to identify the factor structure of psychiatric symptoms of the subjects included in these studies. Subjects were stratified by symptom state according to the DSM-IV criteria. The analysis identified five factors, characterized (in order of variance accounted for) as depression, mania, sleep disturbance, judgment/impulsivity, and irritability/hostility (Swann et al. 2013b). All manic episodes, whether mixed or non-mixed, shared the same factor and cluster structure, differing only in factor scores.

Lithium and haloperidol were chosen as comparators in the included studies because of their proven, evidenced-based use in the treatment of mania. Traditionally, lithium was the major treatment used to ameliorate symptoms of mania by reducing excitatory neurotransmitters (dopamine and glutamate) and is also known for preventing recurrence of manic and depressive episodes (Geddes et al. 2010; Malhi et al. 2013) and reducing the risk of suicide (Tondo and Baldessarini 2000; Cipriani et al. 2013). Haloperidol, a typical antipsychotic, is non-selective and binds to a broad range of receptors, exerting efficacy mainly through the antagonism of dopamine receptors. It is well established as a treatment for acute mania (Cipriani et al. 2011). Aripiprazole is a second-generation atypical antipsychotic with a mechanism of action that differs from other typical and atypical antipsychotics. Aripiprazole is a high-affinity partial agonist of the dopamine D2/D3 receptor, with partial agonist activity at the 5HT1A receptor and antagonist activity at the 5HT2A receptor (Burris et al. 2002; Stark et al. 2007; Tadori et al. 2008). Like lithium, there is evidence that the use of aripiprazole is effective in preventing manic episodes (Goodwin et al. 2011).

The objectives of the post hoc analysis presented here are to use these previously determined factors to characterize the effects of aripiprazole, comparative treatment (haloperidol and lithium), and placebo in the management of bipolar I disorder and to assess the value of early efficacy in predicting efficacy at endpoint (week 3).

**Methods**

**Study design**

This was a post hoc analysis of pooled data from six double-blind, randomized, controlled clinical trials with aripiprazole, which included 2,179 subjects (≥18 years) diagnosed with bipolar I disorder, as defined by the DSM-IV (APA 2000), who were experiencing an acute manic or mixed episode (El Mallakh et al. 2010; Keck et al. 2003; Keck et al. 2009; Sachs et al. 2006b; Vieta et al. 2005; Young et al. 2009) (Table 1). The study protocols, procedures, and consent statements were approved by the Institutional Review Boards (IRBs) of each participating site. Details of the study designs, duration, and treatments are given in Table 1. In all six studies, efficacy assessments included the YMRS total score (primary efficacy outcome) and the MADRS Total score. Factor analysis using YMRS and MADRS line items performed using the principal components method with varimax rotation (Tabachnik and Fidell 2007) identified five factors with eigenvalues >1 (Table 2). These factors were depression (factor 1), mania (factor 2), sleep disturbance (factor 3), judgment/
| Study          | Duration (weeks) | Efficacy assessments (time points) | Study design                                                                                                                                  | Entry criteria | MADRS total score | Treatments                                                                                     |
|---------------|------------------|-----------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------|----------------|-------------------|-----------------------------------------------------------------------------------------------|
| CN138-007     | 3                | Baseline Days 2, 4, 7, 10, 14, 21 | International, multicenter, double-blind, placebo-controlled study in subjects with bipolar I disorder experiencing acute manic or mixed episodes | ≥20 at randomization | –                 | Aripiprazole (flexibly dosed 15 to 30 mg/day) Placebo                                         |
| (Sachs et al. |                  |                                   |                                                                                                                                             |                |                   |                                                                                               |
| 2006a)        |                  |                                   |                                                                                                                                             |                |                   |                                                                                               |
| CN138-009     | 3                | Baseline Days 4, 7, 10, 14, 21    |                                                                                                                                             | –              |                   | Aripiprazole (flexibly dosed 15 to 30 mg/day) Placebo                                         |
| (Keck et al.  |                  |                                   |                                                                                                                                             |                |                   |                                                                                               |
| 2003)         |                  |                                   |                                                                                                                                             |                |                   |                                                                                               |
| CN138-074     | 3                | Baseline Days 7, 10, 14, 21       |                                                                                                                                             | –              |                   | Aripiprazole (fixed dose 15 or 30 mg/day) Placebo                                             |
| (El Mallakh et al. 2010) |      |                                   |                                                                                                                                             |                |                   |                                                                                               |
| CN138-008     | 12               | Baseline Days 4, 7, 10, 5, 6, 8, 10, 12 |                                                                                                                                             | ≥20            | –                 | Haloperidol (5 to 15 mg/day)                                                                  |
| (Vieta et al. |                  |                                   |                                                                                                                                             |                |                   |                                                                                               |
| 2005)         |                  |                                   |                                                                                                                                             |                |                   |                                                                                               |
| CN138-135     | 12               | Baseline Days 2, 4, 7, 5, 6, 8, 10, 12 |                                                                                                                                             | ≥20 at screening and baseline with <25% decrease between visits | ≤17 at screening and baseline with <4-point increase between visits | Aripiprazole (flexibly dosed 15 to 30 mg/day) Placebo (to week 3 only) Lithium (900 to 1,500 mg/day) |
| (Keck et al.  |                  |                                   |                                                                                                                                             |                |                   |                                                                                               |
| 2009)         |                  |                                   |                                                                                                                                             |                |                   |                                                                                               |
| CN138-162     | 12               | Baseline Days 2, 4, 7, 10, 5, 6, 8, 10, 12 |                                                                                                                                             | ≥20 at screening and baseline with <25% decrease between visits | ≤17 at screening and baseline with <4-point increase between visits | Aripiprazole (flexibly dosed 15 to 30 mg/day) Placebo (to week 3 only) Haloperidol (5 to 15 mg/day) |
| (Young et al. |                  |                                   |                                                                                                                                             |                |                   |                                                                                               |
| 2009)         |                  |                                   |                                                                                                                                             |                |                   |                                                                                               |

MADRS, Montgomery-Åsberg Depression Rating Scale; YMRS, Young Mania Rating Scale.
impulsivity (factor 4), and irritability/hostility (factor 5) (Swann et al. 2013b).

### Treatment efficacy

Treatment efficacy was assessed for each treatment (aripiprazole, haloperidol, lithium, and placebo) at baseline, days 4, 7, and 10, and then weekly throughout the study period to reflect clinical decision points for potential treatment change during an acute episode. In the 12-week, active-controlled trials, efficacy was also assessed at day 2 (Table 1). The primary efficacy endpoint was mean change from baseline to week 3 by factor score. The rating scale values (YMRS and MADRS items) at baseline and week 3 were used to run the analyses of covariance (ANCOVA) for mean change from baseline to week 3 by factor for each of the treatments included in these studies, with double-blind treatment and study as main effects, and baseline assessment as covariate. Factor definition is presented in Table 2. All analyses were conducted using the SAS 8.2 statistical analysis program and the last observation carried forward (LOCF).

### Predictive value of early efficacy

Efficacy data were also used to evaluate the ability of early (day 4 and week 1) improvement in factor scores to predict efficacy at endpoint (week 3), using receiver operating characteristic (ROC) curves for percentage change in factor score at day 4 and week 1 in predicting factor response at week 3. Optimal percentage cut-off scores were determined by visual inspection of the ROC curves. Factor response was defined as a 50% improvement (reduction) in factor score from baseline to week 3. Receiver operating characteristic curves were constructed through the use of logistics regression models for each of the three treatment groups: aripiprazole treatment, comparative treatment (haloperidol and lithium combined), and placebo.

The area under the ROC curve (AUC) represents the percentage of randomly drawn pairs from the early improvement time point (day 4/week 1) and endpoint (week 3) that were correctly classified, i.e., where early efficacy was predictive of endpoint efficacy. An AUC of 0.5 would suggest that the test correctly classifies these subjects only 50% of the time, while an AUC of 1 would represent correct classification 100% of the time. Additionally, the ROC curves could be used to identify the optimal percentage change in factor score at day 4/week 1 that best predicts response at week 3, by locating the point on the curve nearest to the perfect classification point of 100% (0 on the x-axis of specificity [false positive rate] and 1 on the y-axis of sensitivity [true positive rate]).

### Results

#### Subjects

Of the 2,179 subjects included in the factor analysis, 2,174 subjects had baseline data and at least one post-baseline efficacy evaluation for inclusion in the efficacy sample. Subjects were assessed following treatment with aripiprazole ($n=1,001$), haloperidol ($n=324$), lithium ($n=155$), and placebo ($n=694$). Treatment continuation varied from 31% to 71% at week 3 of the original studies (El Mallakh et al. 2010; Keck et al. 2003; Keck et al. 2009; Sachs et al. 2006b; Vieta et al. 2005; Young et al. 2009).

---

**Table 2 Factors of bipolar mania identified from aripiprazole studies (Swann et al. 2013b)**

| Factors                        | Scale   | Item                                      |
|-------------------------------|---------|-------------------------------------------|
| (Total % variance)            |         |                                           |
| Factor 1: depression (21.3%)  | MADRS   | Reported sadness                          |
|                               |         | Apparent sadness                          |
|                               |         | Inner tension                             |
|                               |         | Reduced appetite                          |
|                               |         | Lassitude                                 |
|                               |         | Inability to feel                         |
|                               |         | Pessimistic thoughts                      |
|                               |         | Suicidal thoughts                         |
| Factor 2: mania (12.0%)       | MADRS   | Concentration difficulties                |
|                               | YMRS    | Elevated mood                             |
|                               | YMRS    | Increased motor activity                  |
|                               | YMRS    | Speech                                    |
|                               | YMRS    | Language                                  |
|                               | YMRS    | Content                                   |
| Factor 3: sleep disturbance (7.5%) | MADRS   | Reduced sleep                             |
|                               | YMRS    | Sleep                                     |
| Factor 4: judgment/impulsivity (6.7%) | YMRS   | Sexual interest                           |
|                               | YMRS    | Appearance                                |
|                               | YMRS    | Insight                                   |
| Factor 5: irritability/hostility (5.8%) | YMRS   | Irritability                              |
|                               | YMRS    | Disruptive, aggressive behavior           |

All items with factor loading $\geq 0.4$ are shown.

MADRS, Montgomery-Åsberg Depression Rating Scale; YMRS, Young Mania Rating Scale.
Treatment effect on factor score

The effects of treatment on factor scores are shown in Figure 1. Aripiprazole, haloperidol, and lithium significantly improved mania factor scores compared with placebo as indicated by confidence intervals. Improvements between baseline and week 3 in sleep disturbance, judgment/impulsivity, and irritability/hostility factor scores significantly favored aripiprazole and haloperidol treatments compared with placebo, while no significant improvements were observed for lithium compared with placebo (apart from factor 4). Changes in depression factor scores demonstrated the smallest treatment effect across the treatment arms and compared with placebo. Improvements in depression factor scores versus placebo showed a trend for improvement for aripiprazole at week 3 (study endpoint), but the changes did not reach statistical significance (Figure 2).

Predictive value of early efficacy

The AUCs were >0.5 across all factors with all treatments for efficacy at day 4 and week 1 as predictors of response at week 3 (Figure 2). In general, AUCs were greater for week 1 than for day 4. The greatest AUCs for each treatment group observed at day 4 were factor 4 (judgment and impulsivity) for subjects treated with aripiprazole (0.69), factor 5 (irritability/hostility) for subjects receiving haloperidol and lithium (0.70), and factor 2 (mania) for placebo (0.78) (Figure 2). The greatest AUCs for each treatment group observed at week 1 were factor 2 (mania) for subjects treated with aripiprazole or placebo (0.80 and 0.88, respectively) and factor 4 (judgment and impulsivity) for subjects treated with haloperidol and lithium (0.80) (Figure 2). The optimal percentage improvement in factor score at day 4/week 1 for predicting factor response at week 3 was generally approximately 40% to 50% across all factors and treatments (data not shown).

Discussion

In the current analysis, all active treatments (aripiprazole, haloperidol, and lithium) were significantly more effective than placebo for the manic factor (characterized by the classic symptoms of mania, including elevated mood and increased motor activity). A depressed mood factor was shown previously to be a key component of manic or mixed episodes associated with bipolar I disorder in subjects with acute manic or mixed episodes (Swann et al. 2013b). In the current analysis, which corrected for baseline values, the effect of treatment on depressed mood was lower than that seen with other factors. When assessing the depression mood factor, aripiprazole showed an improvement, while subjects in the haloperidol and lithium groups showed worsening compared with placebo. Although none of the changes were significant, the lack of benefit with lithium and higher effectiveness of aripiprazole compared with haloperidol at lowering depressive symptoms is in agreement with previous findings (Swann et al. 2002; Vieta et al. 2005). Bearing in mind the low level of depression at baseline, no meaningful clinical changes were expected and no definitive conclusions can be drawn from the findings presented here with regard to differential efficacy between the treatments.

Interestingly, the irritability/hostility factor - a prominent component of manic episodes - was improved with both aripiprazole and haloperidol compared with placebo. Lithium did not demonstrate improvements in the irritability/hostility factor in this study, raising the question of whether irritability/hostility factor symptoms may differentially respond to therapy. However, a relatively small
effect of lithium and a significant effect of valproate on irritability/hostility have been reported previously (Swann et al. 2002).

The predictive value of response at week 3 was shown to be nearly as good at day 4 as at week 1. Early identification of treatment response or non-response in bipolar disorder may be beneficial to subjects to optimize clinical outcome by allowing identification of subjects that are most likely to substantially benefit from therapy. Similar analyses assessing benefits of early response in subjects with bipolar depression who received aripiprazole showed that the absence of minimal treatment response early during treatment predicted ultimate non-response at study endpoint with high predictive validity (Kemp et al. 2010; Kemp et al. 2011). This is broadly consistent with earlier research treatment using composite mania scores which showed that response to lithium could be predicted at day 7 (Swann et al. 1986).

It has also been shown in subjects with schizophrenia that early treatment response encourages subjects to remain on the treatment longer with a lower rate of treatment discontinuation (Kinon et al. 2008) potentially leading to improved subject functioning and a reduction in overall healthcare costs for these subjects (Ascher-Svanum et al. 2008). Therefore, identifying patients who may not respond to and/or remit on a chosen treatment could be a powerful tool that enables clinicians to formulate treatment regimens that shorten the exposure to ineffective agents or refine the dose of treatments to enhance response. Benefits of early response on the predictive value of treatment response to aripiprazole have been documented for other indications including schizophrenia and major depressive disorder (Correll et al. 2013; Muzina et al. 2011).

In the current study, overlapping confidence intervals suggest similarities in predictive power between treatments; however, no formal statistical testing was performed to directly compare the AUCs between treatments. The predictive value of the placebo response (particularly to factor 2 - mania) at both day 4 and week 1 was notably

Figure 2 Area under the ROC curve. Area under the receiver operating characteristic curve for percent change in factor score at Day 4 (a) and week 1 (b) predicting factor response at week 3. *Confidence interval data not available. AUC, area under the receiver operating characteristic curve; CI, confidence interval.
high. This is perhaps not surprising given that most of the studies (Keck et al. 2003; Keck et al. 2009; Sachs et al. 2006b; Young et al. 2009) included in this analysis required inpatient hospitalization for the first 2 weeks of treatment. Manic subjects responding to placebo at day 4 are more likely to show a sustainable placebo response at Week 3. Symptom improvement in response to placebo could have been enhanced by patients potentially displaying a transient episode of mania or the structured hospital and desti

mulated environment that may have shortened the natural 6- to 12-week duration of a manic episode (Keck et al. 2000; Vieta et al. 2005), as well as high frequency of control visits and the fixed-dose design of the treatment. Analysis of the ROC curves suggests that, in order to achieve a clinically relevant prediction of treatment outcome at week 3, a higher percentage cut-off than the typically used 30% was required. Therefore, the optimal early percentage improvement in factor scores is approximately 40% to approximately 50% from baseline. However, the above observation requires further analyses on large sets of data to establish a clinically meaningful threshold and potentially inform new classifications and sequential treatment strategies for bipolar disorder.

The Research Domain Criteria (RDoC) project (http://nimh.nih.gov/research-priorities/rdoc/index.shtml) has been launched by the National Institute of Mental Health (NIMH) to aid in the development and implementation of new ways of classifying psychopathology and grouping participants in research studies based on dimensions of observable behavior and neurobiological measures. The aim of the project is to create a foundational research literature that informs future versions of nosologies based upon genetics, biomarkers, and behavioral neuroscience. As an initial step, a sufficient research foundation is needed that can eventually inform the best approaches for clinical diagnosis and treatment. Factor analyses such as those presented here, while only using principles of the RDoC, allow for a dimensional approach to the examination of symptoms and associated treatment outcomes that might become the basis for comparisons of outcomes across diagnoses using data from trials that used categorical diagnoses for study entry. The current analysis provides an example of a potential dimensional structure for episodes of bipolar disorder. Factors and factor clusters developed in this manner provide a platform for neurobiological and treatment studies to support research into alternative approaches for assessing psychopathology based on more basic characteristics that may underlie symptomatic presentation of bipolar disorder.

Although the study above was not designed to directly compare treatment outcome between different agents, it may provide a promising construct for future studies to investigate the potential for symptom factors to characterize the effects of treatment on patients with acute mania and to assess the value of early efficacy in predicting treatment outcome. Clinicians and patients are still using the DSM for diagnosis, and the construct of mania is not fully explained by any domain currently in the RDoC. However, data presented here may be relevant to provide both patients and clinicians with the tools to make a more informed decision on short-term and inevitably long-term treatment to maximize patient benefit.

Limitations

This post hoc analysis includes the pooled data of several clinical trials. While this is a limitation, it should be noted that the majority of the studies included (El Mallakh et al. 2010; Keck et al. 2003; Keck et al. 2009; Sachs et al. 2006b; Young et al. 2009) used relatively similar study inclusion criteria and thus resulted in similar subject populations suitable for pooling. However, it should also be considered that the inclusion criteria of the original trials may limit the generalizability of the study findings. The 12-week studies included in this analysis were not powered to detect differences between active treatments at week 3. Subject numbers for haloperidol and lithium were substantially lower than for aripiprazole and placebo and may have limited the power for detecting relationships involving these treatments. Another limitation is the use of LOCF data in the context of investigating symptom change; however, regarding the short duration of these studies and the relatively high completion rate (up to 71% at week 3), LOCF data was deemed suitable to assess efficacy at the indicated time points. The rating scale values (YMRS and MADRS items) at baseline and week 3 were used to run the ANCOVA for mean change from baseline to week 3 by factor for each of the three treatments with double-blind treatment and study as main effects and baseline assessment as covariate. A factor conversion was performed rather than presenting endpoint data as raw score and adjusting for baseline response, or providing the change in score and regressing it on treatment.

Conclusions

This post hoc analysis of data from over 2,000 subjects with manic or mixed episodes associated with bipolar I disorder, enrolled in six double-blind, randomized, controlled clinical trials, confirmed that all active treatments provided significant improvement compared with placebo in at least one factor (mania), with aripiprazole and haloperidol resulting in significant efficacy in four out of the five factors assessed. Early efficacy was found to be predictive of efficacy at week 3 for all treatments across all factors; however, response at week 1 was a better early predictor than response at day 4. This analysis confirms the value of early treatment/assessment across a range of factors from this heterogeneous subject
population and may be useful as a means for examining symptom dimensions in treatment trials across diagnoses. While exploratory, results such as these might be part of future risk prediction models across diagnoses - including characteristics not collected in a clinical trial setting, potential biomarkers, and genetic markers - that might lead to a more precise means of picking treatments and predicting response for our patients.

**Abbreviations**

ANCOVA: analysis of covariance; AUC: area under the ROC curve; DSM-5: Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition; FDA: Food and Drug Administration; LOCF: last observation carried forward; MADRS: Montgomery-Åsberg Depression Rating Scale; NIMH: National Institute of Mental Health; RDoC: The Research Domain Criteria; ROC: receiver operating characteristics; YMRS: Young Mania Rating Scale.

**Competing interests**

MO’s conflicts of interests for the past 36 months include Eli Lilly (consulting - Data Safety Monitoring Board), Janssen Pharmaceutica (consulting), Alexza Pharmaceuticals (consulting), Bristol-Myers Squibb (consulting), and Otsuka America Pharmaceuticals Inc. (consulting). TS’s conflicts of interest include Sunovion Pharmaceuticals, Inc. (research support, consulting), H. Lundbeck A/S (consulting, speaking engagement), Elan Pharmaceuticals (research support), National Institute of Mental Health (research support, grant review), Veterans Affairs Cooperative Studies Program (research support), Johns and Bartlett (royalties), International Society of Bipolar Disorders (Continued Medical Education [CME] lecture), Omnia-Prova Education Collaborative (CME lecture), Healthmanners CME (CME lecture), and Medcape Education (CME lecture). AS’s conflicts of interest include Elan Pharmaceuticals (research support), Bristol-Myers Squibb (consulting, speaker engagement), Lundbeck (consulting, speaker engagement), Pfizer Laboratories (consulting - Data Safety Monitoring Board), Teva Pharmaceuticals (consulting - Data Safety Monitoring Board); and Merck (consulting, speaker engagement). JE and BC are employees of Bristol-Myers Squibb. WL and RB are employees of Otsuka Pharmaceutical Europe Ltd. and Otsuka America Pharmaceutical Inc., respectively.

**Authors’ contributions**

MO, AS, and TS contributed to the initial study formulation, consultation, analysis design, interpretation of results, and the development, writing, and review of the manuscript. JE performed the statistical analysis and contributed to the analysis design, manuscript review, and interpretation of results. BC and RB contributed to the analysis design, data review, and manuscript development. WL contributed to the data review and manuscript development. In line with publication guidelines, all authors contributed to manuscript development and final draft approval. All authors read and approved the final manuscript.

**Acknowledgements**

The authors would like to thank Sabrina Marler, a former employee of Bristol-Myers Squibb, for her contributions in the statistical analysis of the data. This study was supported by Otsuka Pharmaceutical Europe Ltd. The first draft was created by author collaboration. Further editorial support for the preparation of this manuscript was provided by Ogilvy Healthworld Medical Education; funding was provided by Otsuka Pharmaceutical Europe Ltd.

**Author details**

1VA Palo Alto Health Care System, 3801 Miranda Avenue, Mail Code 151 T, Building 4, 3rd Floor, Palo Alto, CA 94304, USA. 2Stanford University School of Medicine, Stanford, CA, USA. 3Department of Psychiatry and Behavioral Sciences, Baylor College of Medicine, 1977 Butler Blvd Suite E4.400, Houston, TX 77030, USA. 4AstraZeneca, 601 Office Center Drive Suite 200, Fort Washington, PA 19034, USA. 5Otsuka Pharmaceutical Europe Ltd., Gallions – 1st Floor Wexham Springs Framwood Road, London, Wexham SL3 6P), UK. 6Otsuka Pharmaceutical Development & Commercialization, Inc., 508 Carnegie Center, Princeton, NJ 08540, USA. 7Bristol-Myers Squibb, P.O. Box 5200, Princeton, NJ 08543-5200, USA.

**References**

APA: Diagnostic and Statistical Manual of Mental Disorders DSM-IV-TR Fourth Edition (Text Revision). Washington, DC: American Psychiatric Publishing, Inc., 2000.

APA. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th ed. Arlington, VA: American Psychiatric Publishing; 2013.

Ascher-Svanum H, Nyhuis AW, Faries DE, Kinnamon BJ, Baker RW, Shekhar A. Clinical, functional, and economic ramifications of early nonresponse to antipsychotics in the naturalistic treatment of schizophrenia. Schizophr Bull. 2008;34:1163–71.

Azorin JM, Kaladjian A, Adda M, Hantouche E, Hamen A, Lancrenon S, et al. Towards the delineation of mania subtypes in the French National EPIMAN-II Mille Cohort. Comparisons with prior cluster analytic investigations. Eur Arch Psychiatry Clin Neurosci. 2008;258:497–504.

Bertochy N, Gervasoni N, Favre S, Liberek C, Raga-Pardos E, Aubry JM, et al. Phenomenology of mixed states: a principal component analysis study. Bipolar Disord. 2009;7:907–12.

Burris KD, Molski TF, Xu C, Ryan E, Totton K, Kikuchi T, et al. Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. J Pharmacol Exp Ther. 2002;302:381–9.

Cassidy F, Forest K, Muny E, Carroll BJ. A factor analysis of the signs and symptoms of mania. Arch Gen Psychiatry. 1998;55:73–32.

Cianni A, Barbu C, Salani G, Rendell J, Brown R, Stockton S, et al. Comparative efficacy and acceptability of antinamic drugs in acute mania: a multiple-treatments meta-analysis. Lancet. 2011;378:1306–15.

Cianni A, Hawton K, Stockton S, Geddes JR. Lithium in the prevention of suicide in mood disorders: updated systematic review and meta-analysis. BMJ. 2013;346:f6466.

Correll CU, Zhao J, Carson W, Marcus R, McQuade R, Forbes RA, et al. Early antipsychotic response to aripiprazole in adolescents with schizophrenia: predictive value for clinical outcomes. J Am Acad Child Adolesc Psychiatry. 2013;52:689–98.

Diataver SC, Chen YR, Shoab AM, Swann AC. Phenomenology of mania: evidence for distinct depressed, dysphoric, and euphoric presentations. Am J Psychiatry. 1993;150:926–30.

El Mallakh RS, Vieta E, Rollin L, Marcus R, Carson WH, McQuade R. A comparison of two fixed doses of aripiprazole with placebo in acutely relapsed, hospitalized patients with bipolar disorder I (manic or mixed) in subpopulations (CN138-007). Eur Neuropsychopharmacol. 2010;20:776–83.

Geddes JR, Goodwin GM, Rendell J, Azorin JM, Cianni A, Ostacher MJ, et al. Lithium plus valproate combination therapy versus monotherapy for relapse prevention in bipolar I disorder (BALANCE): a randomised open-label trial. BALANCE investigators and collaborators. Lancet. 2010;375:385–95.

Goodwin GM, Abbar M, Schlaepfer TE, Gunter H, Lucht RW, Belliver F, et al. Aripiprazole in patients with bipolar mania and beyond: an update of practical guidance. Curr Med Res Opin. 2011;27:2285–99.

Grunze H, Vieta E, Goodwin GM, Bowden C, Licht RW, Morrell HJ, et al. The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: update 2009 on the treatment of acute mania. World J Biol Psychiatry. 2009;10:85–116.

Harvey PD, Endicott JM, Loebel AD. The factor structure of clinical symptoms in bipolar I disorder. Toward the delineation of mania subtypes and potential biomarkers - that might lead to a more precise means of picking treatments and predicting response for our patients. Psychiatric Clin Neurosci. 2008;62:497–504.

Henderson LM, Strakowski SM. Randomized, controlled studies of acute bipolar mania and depression, Biol Psychiatry. 2000;47:748–55.

Keck PE, Welge JA, McElyow SL, Arnold LM, Keck PE, Marcus R, Toukdomitris S, Ali M, Liebeskind A, Saha A, et al. A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole in patients with acute bipolar mania. Am J Psychiatry. 2003;160:1651–6.

Keck PE, Oruluk PJ, Cutler AJ, Sanchez R, Torbeys A, Marcus RN, et al. Aripiprazole monotherapy in the treatment of acute bipolar I mania: a randomized, double-blind, placebo- and lithium-controlled study. J Affect Disord. 2009;112:36–49.

Kemp DE, Calabrese JR, Eudicone JM, Ganocy S, Tran QV, McQuade RD, et al. Predictive value of early improvement in bipolar depression trials: a post-hoc analysis of covariance; AUC: area under the ROC curve; DSM-5: Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition; FDA: Food and Drug Administration; LOCF: last observation carried forward; MADRS: Montgomery-Åsberg Depression Rating Scale; NIMH: National Institute of Mental Health; RDoC: The Research Domain Criteria; ROC: receiver operating characteristics; YMRS: Young Mania Rating Scale.

Received: 22 January 2015 Accepted: 31 March 2015

Published online: 05 May 2015

Correlation F, Forest K, Muny E, Carroll BJ. A factor analysis of the signs and symptoms of mania. Arch Gen Psychiatry. 1998;55:27–32.

Cassidy F, Forest K, Muny E, Carroll BJ. A factor analysis of the signs and symptoms of mania. Arch Gen Psychiatry. 1998;55:27–32.

Cassidy F, Forest K, Muny E, Carroll BJ. A factor analysis of the signs and symptoms of mania. Arch Gen Psychiatry. 1998;55:27–32.

Cassidy F, Forest K, Muny E, Carroll BJ. A factor analysis of the signs and symptoms of mania. Arch Gen Psychiatry. 1998;55:27–32.
Tadori Y, Forbes RA, McQuade RD, Kikuchi T. Characterization of aripiprazole partial agonist activity at human dopamine D3 receptors. Eur J Pharmacol. 2008;597:27–33.

Mali GS, Tamious M, Das P, Coulston CM, Berk M. Potential mechanisms of action of lithium in bipolar disorder. Current understanding. CNS Drugs. 2013;27:135–53.

McElroy SL, Keck PE, Pope HGJ, Hudson JI, Faedda GL, Swann AC. Clinical and research implications of the diagnosis of dysphoric or mixed mania or hypomania. Am J Psychiatry. 1992;149:1633–44.

Muzina DJ, Chambers J, Camacho T, Eudicone J, Forbes R, Berman R, et al. Adjunctive aripiprazole for depression: predictive value of early assessment. Am J Manag Care. 2011;17:791–801.

Rossi A, Daneluzzo E, Arudi L, Di Domenico M, Pollice R, Petrucci C. A factor analysis of the signs and symptoms of the manic episode with Bech-Rafaelsen Mania and Melancholia Scales. J Affect Disord. 2001;64:267–70.

Sachs G, Bowden C, Calabrese JR, Ketter TA, Thompson T, White R, et al. Effects of lamotrigine and lithium on body weight during maintenance treatment of bipolar I disorder. Bipolar Disord. 2006a;8:175–81.

Sachs G, Sanchez R, Marcus R, Stock E, McQuade R, Carson W, et al. Aripiprazole in the treatment of acute manic or mixed episodes in patients with bipolar I disorder: a 3-week placebo-controlled study. J Psychopharmacol. 2006b;20:536–46.

Sato T, Bottender R, KleinDJenat N, Moeller HJ. Syndromes and phenomenological subtypes underlying acute mania: a factor analytic study of 576 manic patients. Am J Psychiatry. 2002;159:968–74.

Stark AO, Jordan S, Allers KA, Bertejak RL, Chen R, Mistry Kannan T, et al. Interaction of the novel antipsychotic aripiprazole with S-HT(1A) and S-HT (2A) receptors: functional receptor-binding and in vivo electrophysiological studies. Psychopharmacology (Berl). 2002;160:377–85.

Swann AC, Secunda SK, Katz MM, Koslow SH, Maas JW, Chang S, et al. Lithium treatment of mania: clinical characteristics, specificity of symptom change, and outcome. Psychiatry Res. 1986;18:127–41.

Swann AC, Janicak PL, Calabrese JR, Bowden CL, Dilsaver SC, Morris DO, et al. Structure of mania: depressive, irritable, and psychotic clusters with different retrospectively-assessed course patterns of illness in randomized clinical trial participants. J Affect Disord. 2001;67:123–32.

Swann AC, Bowden CL, Calabrese JR, Dilsaver SC, Morris DO. Pattern of response to divalproex, lithium, or placebo in four naturalistic subtypes of mania. Neuropsychopharmacology. 2002;26:530–6.

Swann AC, Steinberg JL, Lifjiffijt M, Moeller G. Continuum of depressive and manic mixed states in patients with bipolar disorder: quantitative measurement and clinical features. World Psychiatry. 2009;8:66–72.

Swann AC, Lafer B, Perugi G, Fieve RA, Bauer M, Bahk WM, et al. Bipolar mixed states: an international society for bipolar disorders task force report of symptom structure, course of illness, and diagnosis. Am J Psychiatry. 2013a;170:31–42.

Swann AC, Suppes T, Ostacher M, Eudicone JM, McQuade R, Forbes RA, et al. Multivariate analysis of bipolar mania: retrospectively assessed structure of bipolar I manic and mixed episodes in randomized clinical trial participants. J Affect Disord. 2013b;144:59–64.

Tabachnik BG, Fidell LS. Using multivariate statistics. 5th ed. Boston, MA: Allyn & Bacon; 2007.

Tadori Y, Forbes RA, McQuade RD, Kikuchi T. Characterization of aripiprazole partial agonist activity at human dopamine D3 receptors. Eur J Pharmacol. 2008;597:27–33.

Tonto L, Baldessarini RJ. Reduced suicide risk during lithium maintenance treatment. J Clin Psych. 2000;61 Suppl 9:97–104.

Viete E, Bourin M, Sanchez R, Marcus R, Stock E, McQuade RD, et al. Effectiveness of aripiprazole v. haloperidol in acute bipolar mania: Double-blind, randomised, comparative 12-week trial. Br J Psychiatry. 2005;187:235–42.

Young AH, Oren DA, Lowy A, McQuade RD, Marcus RN, Carson WH, et al. Aripiprazole monotherapy in acute mania: 12-week randomised placebo- and haloperidol-controlled study. Br J Psychiatry. 2009;194:40–8.